Dr. Ron Cohen isn’t easily deterred. The physician-turned-executive has spent decades in the biotech industry and weathered a number of setbacks – he learned in his early years at the now-defunct Advanced Tissue Sciences that to succeed, he needed resilience.
“I learned that it took hundreds of millions of dollars if not billions to develop a single drug successfully. I learned that the odds of success were approximately 10%. I learned that even if you were successful it probably was going to take you, on average, between 10 and 15 years,” he told Drug Delivery Business News. “And I thought that was great.”
The discouraging statistics on drug development didn’t dissuade Cohen in part because he saw it as a chance to try to bring cutting-edge science out of the laboratory and make it work for patients.
Get the full story at our sister site, Drug Delivery Business News.
The post Acorda’s CEO on failure, perseverance and the profound risks of drug development appeared first on MassDevice.
from MassDevice https://ift.tt/2v6uMgb
Cap comentari:
Publica un comentari a l'entrada